Combination therapy targeting cancer associated with the hedgehog pathway
OwnerJaeyoung Yooninventor
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of treating a cancer associated with the hedgehog (Hh) pathway are described, as are methods of overcoming resistance to single therapy treatment of a cancer associated with hedgehog (Hh) pathway, and methods of rescuing treatment of a cancer resistant to single therapy treatment, using at least two antineoplastic agents targeting the Hh pathway.
Claims35
A method of treating a cancer associated with a hedgehog (Hh) pathway in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a first antineoplastic agent targeting a component of the Hh pathway, and a therapeutically effective amount of a second antineoplastic agent targeting a component of the Hh pathway, wherein the component of the Hh pathway is selected from Sonic Hedgehog (SHH), a receptor, Patched (PTCH1 and PTCH2), a transmembrane protein, Smoothened (SMO) and gene expression regulators, glioma associated oncogene transcription factors (GLI1, GLI2, GLI3), growth arrest specific protein 1 (GAS1), Cell Adhesion Associated, Oncogene Regulated (CDON), Brother of CDO (BOC), SUFU Negative Regulator Of Hedgehog Signaling (SUFU), Kinesin Family Member 7 (Kif7), hedgehog-interacting protein (HHIP1), and Speckle-Type POZ Protein (SPOP).
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of treating a cancer in a subject in need thereof, the method comprising administering to a subject in need thereof an antineoplastic therapy comprising a first antineoplastic agent and a second antineoplastic agent each targeting the Hh pathway, wherein each of the two antineoplastic agents targets a different mechanism of the Hh pathway, and wherein the combined treatment with the first and the second antineoplastic agent overcomes a demonstrated resistance of the cancer to treatment with either the first or the second antineoplastic agent when administered as a monotherapy, or prevents development of resistance of the cancer to treatment with either the first or the second antineoplastic agent when administered as a monotherapy.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.